- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06599736
En studie av RhinAer Stylus for behandling av kronisk rhinitt (BIOKLEAR)
Effekt av temperaturkontrollert radiofrekvensablasjon av den bakre nesenerven på inflammatoriske biomarkører hos pasienter med allergisk og ikke-allergisk kronisk rhinitt
Post-market study to continue to evaluate the effectiveness of the RhinAer Stylus for chronic rhinitis and the effect of treatment on inflammatory biomarkers.
Studieoversikt
Detaljert beskrivelse
Prospective, Open Label, Multicenter Study of the Aerin Medical RhinAer® Stylus for Chronic Rhinitis to continue to evaluate the effectiveness of the RhinAer® Stylus for treating the posterior nasal nerve area to improve symptoms in adults diagnosed with chronic rhinitis.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Colorado
-
Colorado Springs, Colorado, Forente stater, 80923
- Colorado ENT & Allergy
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45267
- University of Cincinnati
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Age 22 to 85 years (inclusively).
-
Willing and able to provide informed consent.
-
Willing and able to comply with the patient-specific requirements outlined in the study protocol.
-
Presenting to the ENT office seeking evaluation and/or treatment for chronic rhinitis (allergic or nonallergic) of at least 12 months duration
-
Willing to undergo the RhinAer procedure
-
Has a baseline rTNSS symptom score of ≥6 at time of screening
-
If on anticoagulation therapy, anticoagulant medications can be withheld during the perioperative period (at least 3-day window pre- and post-procedure).
-
Has been diagnosed with either allergic or non-allergic chronic rhinitis and meet the following criteria:
- a. Allergic rhinitis: diagnosed with perennial (non-seasonal) allergic rhinitis and has demonstrated sensitization to specific allergens through skin prick testing, specific IgE blood testing, or other allergy testing methods, confirming the allergic nature of their rhinitis within the past 24 months.
OR
-b. Nonallergic rhinitis: diagnosed with nonallergic rhinitis with demonstration of a negative skin prick testing, specific IgE blood testing, or other allergy testing methods, confirming the nonallergic nature of their rhinitis within the past 24 months.
Exclusion Criteria:
- Anatomic obstructions in the nasal passage(s) that in the investigator's opinion limits access to the posterior nasal nerve treatment area.
- Has seasonal rhinitis symptoms.
- Current or recent use of biologic therapy within past 3 months.
- History of chronic epistaxis or has had episodes of significant nose bleeds in the past 3 months.
- Known or suspected allergies or contraindications to the anesthetic agents and/or antibiotic medications to be used during the study procedure.
- Known or suspected to be pregnant or is lactating.
- Has any condition resulting in a predisposition to excessive bleeding (e.g., hereditary hemorrhagic telangiectasia [HHT]).
- Has diagnosis of rhinitis medicamentosa, an active nasal or sinus infection or has a history of 'dry eye.'
- Has had previous procedure or surgery for chronic rhinitis (e.g., PNN ablation).
- Has had a nasal or sinus surgical procedure in the past six (6) months.
- Currently participating in another clinical research study or has participated in an interventional study within the past 3 months.
- Has a planned adjunctive procedure at the time of the study procedure or within the 6-month study follow-up period
- Other medical conditions which in the opinion of the investigator would predispose the patient to poor wound healing, increased surgical risk, or poor compliance with the requirements of the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: RhinAer Stylus treatment
The RhinAer procedure will be performed in the study clinic using the RhinAer Stylus and Aerin Console. The RhinAer Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants will have both nostrils treated in the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve. |
The RhinAer procedure incorporates use of the RhinAer Stylus (Model FG1393, CAT1394), which is a 510(k) cleared (FDA - K221907) disposable handheld device capable of delivering bipolar radiofrequency energy to tissue. The Aerin Console (Model FG226) RF generator with temperature control capable of delivering very low doses of energy is also cleared for use in the US (FDA - K162810). |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in Nasal Secretion Inflammatory Biomarker Levels at 3 Months Following Temperature-Controlled Radiofrequency (TCRF) Treatment
Tidsramme: Baseline (pre-procedure) and 3 months post-procedure
|
Changes from baseline to 3 months post-procedure in nasal secretion inflammatory biomarker levels were evaluated in patients with allergic and nonallergic chronic rhinitis by assessing the change from baseline in mean fluorescence intensity (MFI) for each biomarker. The following biomarkers were assessed: epidermal growth factor (EGF), interferon-gamma (IFNγ), interleukins (IL-1β, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IL-17A, IL-17F, IL-22, IL-25), tumor necrosis factor-alpha (TNFα), transient receptor potential vanilloid 1 (TRPV-1), and immunoglobulin E (IgE). |
Baseline (pre-procedure) and 3 months post-procedure
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- CTP1938
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
No data collected will be shared with other researchers participating in the study.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .